SEK 37.0
(-1.99%)
Year | Revenue | Revenue Growth |
---|---|---|
2023 | 423 Thousand DKK | -93.5% |
2022 | 6.51 Million DKK | -32.27% |
2021 | 9.61 Million DKK | 0.0% |
2020 | - DKK | 0.0% |
2019 | - DKK | 0.0% |
2018 | - DKK | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2024 Q2 | 1 Million DKK | 3746.15% |
2024 Q1 | 26 Thousand DKK | -80.3% |
2023 Q3 | 66 Thousand DKK | -58.49% |
2023 FY | 423 Thousand DKK | -93.5% |
2023 Q4 | 132 Thousand DKK | 100.0% |
2023 Q2 | 159 Thousand DKK | 140.91% |
2023 Q1 | 66 Thousand DKK | 0.0% |
2022 FY | 6.51 Million DKK | -32.27% |
2022 Q3 | 66 Thousand DKK | -97.82% |
2022 Q2 | 3.02 Million DKK | -9.7% |
2022 Q1 | 3.35 Million DKK | 95.0% |
2022 Q4 | 66 Thousand DKK | 0.0% |
2021 Q3 | 1.6 Million DKK | 0.0% |
2021 Q2 | - DKK | 0.0% |
2021 Q1 | - DKK | 0.0% |
2021 FY | 9.61 Million DKK | 0.0% |
2021 Q4 | 1.71 Million DKK | 7.24% |
2020 FY | - DKK | 0.0% |
2020 Q4 | - DKK | 0.0% |
2020 Q3 | - DKK | 0.0% |
2020 Q2 | - DKK | 0.0% |
2020 Q1 | - DKK | 0.0% |
2019 Q4 | - DKK | 0.0% |
2019 Q3 | - DKK | 0.0% |
2019 Q2 | - DKK | 0.0% |
2019 Q1 | - DKK | 0.0% |
2019 FY | - DKK | 0.0% |
2018 Q4 | - DKK | 0.0% |
2018 Q3 | - DKK | 0.0% |
2018 FY | - DKK | 0.0% |
2018 Q2 | - DKK | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
AddLife AB (publ) | 9.68 Billion SEK | 99.996% |
Biotage AB (publ) | 1.86 Billion SEK | 99.977% |
Bonesupport Holding AB (publ) | 591.07 Million SEK | 99.928% |
Doxa AB (publ) | 9.9 Million SEK | 95.727% |
Elekta AB (publ) | 18.11 Billion SEK | 99.998% |
iZafe Group AB (publ) | 1.82 Million SEK | 76.784% |
Ortivus AB (publ) | 84.08 Million SEK | 99.497% |
Ortivus AB (publ) | 84.08 Million SEK | 99.497% |
Q-linea AB (publ) | 4.44 Million SEK | 90.473% |
S2Medical AB (publ) | 6.97 Million SEK | 93.932% |
Synsam AB (publ) | 5.9 Billion SEK | 99.993% |